Adderall 30 mg delivers a balanced formulation of four distinct amphetamine salts engineered to provide potent central nervous system stimulation. By targeting catecholaminergic pathways in the brain, Adderall regulates frontostriatal circuits responsible for executive function, sustained attention, and motor impulse regulation in both pediatric and adult patient populations.<\/p>\n
Clinical Profile & Active Formulation<\/b><\/p>\n Active Ingredients (30 mg Total Formulation):<\/b><\/p>\n Dextroamphetamine Saccharate: 7.5 mg<\/p>\n<\/li>\n Amphetamine Aspartate Monohydrate: 7.5 mg<\/p>\n<\/li>\n Dextroamphetamine Sulfate: 7.5 mg<\/p>\n<\/li>\n Amphetamine Sulfate: 7.5 mg<\/p>\n<\/li>\n Yields 18.75 mg total amphetamine base equivalent, maintaining a standardized 3:1 ratio of the dextro- ($d$<\/span>-) to levo- ($l$<\/span>-) optical isomers.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n Dosage Forms & Physical Identification:<\/b><\/p>\n Immediate-Release (IR):<\/i> Round or oval, peach\/orange biconvex scored tablet, debossed with recognizable manufacturer identifiers (e.g., “b 974 \/ 30” or “dp 30”).<\/p>\n<\/li>\n Extended-Release (XR):<\/i> Two-piece hard gelatin capsule (opaque natural\/orange) containing equal ratios of immediate-release and delayed-release enteric-coated pellets.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n Mechanism of Action & Neurobiology:<\/b> Acts primarily by promoting the presynaptic release of dopamine and norepinephrine into the synaptic cleft. It competitively inhibits the dopamine active transporter ($\\text{DAT}$<\/span>) and norepinephrine transporter ($\\text{NET}$<\/span>), reverses vesicular monoamine transporter 2 ($\\text{VMAT}_2$<\/span>) flow, and weakly inhibits monoamine oxidase ($\\text{MAO}$<\/span>), resulting in sustained monoaminergic signaling in the prefrontal cortex.<\/p>\n<\/li>\n Farmacokinetiek:<\/b> Rapid gastrointestinal absorption with peak plasma concentrations ($C_{\\max}$<\/span>) achieved within approximately 3 hours for immediate-release tablets (and ~7 hours for extended-release capsules). Metabolized hepatically via CYP2D6 and flavin-containing monooxygenase pathways; elimination half-life ranges from 10 to 13 hours for $d$<\/span>-amphetamine and 13 to 16 hours for $l$<\/span>-amphetamine, with excretion heavily influenced by urinary pH.<\/p>\n<\/li>\n<\/ul>\n Indications & Clinical Prescribing Guidelines<\/b><\/p>\n Attention Deficit Hyperactivity Disorder (ADHD):<\/b> Indicated as an integral component of a comprehensive treatment program including educational, behavioral, and psychological interventions.<\/p>\n<\/li>\n Narcolepsy:<\/b> Indicated for the symptomatic control of daytime hypersomnolence and uncontrollable sleep episodes.<\/p>\n<\/li>\n Dosing Protocols:<\/b> Therapy must be titrated to the lowest effective therapeutic dose. Doses are typically scheduled early in the day to minimize nocturnal sleep disturbances and insomnia.<\/p>\n<\/li>\n<\/ul>\n Important Safety Information & Boxed Warnings<\/b><\/p>\n Addiction, Abuse, and Misuse:<\/b> Adderall is a Schedule II controlled substance carrying high liability for misuse, abuse, and diversion, which can lead to substance use disorders, cardiovascular collapse, and fatal overdose.<\/p>\n<\/li>\n Cardiovascular Risks & Sudden Death:<\/b> CNS stimulants are associated with sudden death in patients with pre-existing structural cardiac abnormalities, cardiomyopathy, or serious cardiac rhythm disorders. Avoid prescribing to patients with symptomatic cardiovascular disease or moderate-to-severe hypertension.<\/p>\n<\/li>\n Psychiatric Adverse Events:<\/b> May precipitate or exacerbate pre-existing psychotic symptoms, manic episodes in bipolar illness, or emerging aggressive behaviors at therapeutic dosages.<\/p>\n<\/li>\n MAOI Contraindication:<\/b> Co-administration with Monoamine Oxidase Inhibitors (MAOIs) or use within 14 days of MAOI cessation is strictly contraindicated due to the risk of severe hypertensive crisis.<\/p>\n<\/li>\n<\/ul>\n\n \n
\n
\n
\n
\n